Cargando…

Hydroxychloroquine/lopinavir/ritonavir: Vomiting and QTc-interval prolongation following off-label therapy: 2 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178049/ http://dx.doi.org/10.1007/s40278-021-96904-2

Ejemplares similares

Chloroquine/lopinavir/ritonavir/umifenovir: QTc interval prolongation, drug interaction and off-label use: 2 case reports
Publicado: (2020)

Hydroxychloroquine: Prolonged QTc interval following off-label use: case report
Publicado: (2020)

Hydroxychloroquine: QTc interval prolonged following off label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Nausea and vomiting following off label use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Hydroxychloroquine: Borderline prolongation of QTc interval during off-label treatment: case report
Publicado: (2020)

Hydroxychloroquine: QTc prolongation following off-label-use: case report
Publicado: (2020)

Hydroxychloroquine: QTc-prolongation following an off-label use: case report
Publicado: (2020)

Hydroxychloroquine: QTc prolongation following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir/umifenovir: Nausea, vomiting and diarrhoea following off-label treatment: case report
Publicado: (2021)

Atazanavir/ritonavir: QTc prolongation following off-label treatment: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Complete atrioventricular-block, torsades-de-pointes and QT-interval-prolongation following off label use: 2 case reports
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)

Azithromycin/hydroxychloroquine: QTc interval prolongation and torsades de pointes following off-label use: case report
Publicado: (2020)

Hydroxychloroquine: Persistent increase in QTc interval following off-label use: case report
Publicado: (2022)

Hydroxychloroquine: Acute kidney injury, prolonged QTC interval and renal phospholipidosis following off-label use: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Brugada-like ECG pattern following off-label use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Drug ineffectiveness following off-label use in COVID-19 infection: case report
Publicado: (2022)

Hydroxychloroquine: Sinus bradycardia and QTc prolongation following off-label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc prolongation following off-label use: 2 case reports
Publicado: (2021)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc interval prolongation: case report
Publicado: (2021)

Lopinavir/ritonavir: Hyperlipidaemia following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report
Publicado: (2020)

Lopinavir/ritonavir: Diarrhoea following off label use: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine/tocilizumab: QTc prolongation and off label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine: QTc prolongation and off label use: 3 case reports.
Publicado: (2021)

Azithromycin/hydroxychloroquine: QTc prolongation during off-label treatment: case report
Publicado: (2021)

Azithromycin/hydroxychloroquine: Prolonged QTc during off label use: case report
Publicado: (2021)

Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
por: Zequn, Zheng, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir/methylprednisolone: Manic episode with psychotic features during an off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Maculopapular rash following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Cardiotoxicities following off-label use: 4 case reports
Publicado: (2021)

Lopinavir/ritonavir: Hepatic cytolysis following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Lichen planus following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Hydroxychloroquine: Right bundle branch block and QTc prolongation following off label use: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4f59o82doeb48im955lorqi4di